Can a cancer drug make radioactive iodine work again for thyroid tumors?

NCT ID NCT02152995

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether the targeted drug trametinib can help radioactive iodine (I-131) work better in people with advanced thyroid cancer that has returned or spread. The study includes 34 participants whose cancer no longer responds to standard radioactive iodine treatment. The goal is to see if trametinib can increase iodine uptake in tumors, potentially slowing cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
trametinib (a targeted cancer drug) combined with radioactive iodine (I-131)
What this could lead to
If it works, this could make radioactive iodine treatment more effective for people with advanced thyroid cancer that has stopped responding to standard therapy.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The combination may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC THYROID GLAND CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.